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Abstract 
MRI-based markers of schizophrenia have been repeatedly shown to separate patients from 
healthy controls at the single-subject level, but it remains unclear whether these markers reliably 
distinguish schizophrenia from mood disorders across the life span and generalize to new patients 
as well as to early stages of these illnesses. The current study used structural MRI-based multivar-
iate pattern classification to (1) identify and cross-validate a differential diagnostic signature sepa-
rating patients with first-episode and recurrent stages of schizophrenia (SZ, N=158) from patients 
with major depression (MD, N=104), and (2) quantify the impact of major clinical variables, includ-
ing disease stage, age of disease onset and accelerated brain aging on the signature’s classifica-
tion performance. This diagnostic MRI signature was then evaluated in an independent patient co-
hort from two different centers to test its generalizability to bipolar disorder (BIP, N=35), first-
episode psychosis (FEP, N=23) and clinically defined at-risk mental states (ARMS, N=89). Neuro-
anatomical diagnosis was correct in 80% / 72% of MD / SZ patients and involved a pattern of pre-
fronto-temporo-limbic volume reductions and premotor, somatosensory and subcortical increments 
in SZ vs. MD. Diagnostic performance was not influenced by the presence of depressive symp-
toms in SZ and psychotic symptoms in MD, but earlier disease onset and accelerated brain aging 
promoted misclassification in MD due to an increased neuroanatomical SZ likeness of these pa-
tients. Furthermore, disease stage significantly moderated neuroanatomical diagnosis as recur-
rently-ill patients had higher misclassification rates (MD: 23%; SZ: 29%) than first-episode patients 
(MD: 15%; SZ: 12%). Finally, the trained biomarker classified 74 % of the BIP patients as MD, 
while 83% / 77% / 61% of the FEP / ultra-high risk / low-risk ARMS individuals were labeled as SZ. 
Our findings suggest that neuroanatomical information may provide generalisable diagnostic tools 
distinguishing schizophrenia from mood disorders early in the course of psychosis. Disease 
course-related variables such as age of disease onset and disease stage as well alterations of 
structural brain maturation may strongly impact on the neuroanatomical separability of major de-
pression and schizophrenia. 
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Introduction 
Psychiatric diagnoses arise from complex clinical processes and hence are prone to errors 
(Freedman et al., 2013), depending on the patient’s symptoms, the interviewer’s experience and 
the classification systems’ normative validity. Biological data so far only served the exclusion of 
somatic pathologies, leaving the question unanswered whether individualized differential diagnosis 
could benefit from the analysis of complex neurodiagnostic patterns (Fu and Costafreda, 2013; 
Perkins et al., 2014). Furthermore, pattern analysis could unveil overlaps between and heterogene-
ity within diagnoses, thus promoting the revision of psychiatric nosology, and ultimately the con-
vergence of neuroscientific and clinical observation (Krystal and State, 2014). 
Phenomenological heterogeneity particularly characterizes schizophrenic psychoses and 
mood disorders (Linscott and Os, 2010; Murray et al., 2005): Affective symptoms are a core fea-
ture of prodromal (Addington et al., 2014; Schultze-Lutter et al., 2007) and established schizophre-
nia (Baynes et al., 2000; Chemerinski et al., 2008; Cotton et al., 2012; Marengo et al., 2000; Romm 
et al., 2010; Sönmez et al., 2013) while psychotic symptoms frequently coalesce with mania and 
depression (Goodwin and Jamison, 2007; Ohayon and Schatzberg, 2002). At the brain level, het-
erogeneity appears as subgrouping and cross-nosological effects, including neuroanatomical cor-
relates of different symptom dimensions (Koutsouleris et al., 2008; Nenadic et al., 2012; Zhang et 
al., 2014), overlapping and segregating structural abnormalities (Bora et al., 2008, 2010; Du et al., 
2012; Hulshoff Pol et al., 2012; Yu et al., 2010) and gradual transitions of brain activation patterns 
between diagnostic entities (Brandt et al., 2014). Clinically, this heterogeneity may contribute to 
diagnostic uncertainty along the diversity of possible disease trajectories (Baca-Garcia et al., 2007; 
Pope et al., 2013; Salvatore et al., 2013). Scientifically, it challenged the detection of diagnostically 
specific neurobiological markers and hence questioned the validity of the current disease taxono-
my (Keshavan and Brady, 2011; Linscott and Os, 2010), suggesting that unipolar depression, bipo-
lar disorder and schizophrenia may represent ‘stages’ or domains’ along a phenotypic and neuro-
biological disease continuum (Green et al., 2009; Häfner et al., 2005; Lin et al., 2013).  
To simultaneously address this debate and close the translational gap between neurobiologi-
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cal findings and their clinical application, researchers increasingly employed multivariate pattern 
analysis (MVPA) to quantify the sensitivity, specificity and generalisability of diagnostic brain signa-
tures (Bray et al., 2009; Fu and Costafreda, 2013) rather than describing them in terms of their 
constituents’ group-level significance (Davatzikos, 2004). Using MVPA, the field recently demon-
strated a high separability of different neuropsychiatric conditions vs. healthy controls, thus fore-
shadowing a potential translation of neuroimaging findings into diagnostic tools (Kambeitz et al., 
2015; Orrù et al., 2012). However, doubts remain whether MVPA-based biomarkers are really use-
ful in discriminating neuropsychiatric illness from mental well-being, or whether they are rather 
needed as objective tools for a more reliable differential diagnosis (Savitz et al., 2013). Initial find-
ings suggest that neuroimaging may aid in individually separating schizophrenia from bipolar dis-
order (Schnack et al., 2014) and major depression (Ota et al., 2013) or bipolar from unipolar de-
pression (Grotegerd et al., 2013; Mourão-Miranda et al., 2012; Serpa et al., 2014). However, as 
these studies focused on pairwise comparisons it remains unclear how the reported neurodiagnos-
tic signatures would perform in patients with ‘intermediate’ phenotypes and early disease states as 
well as in populations broadly covering the different age windows of these phenotypes. 
An established approach to measure how clinical intersections, disease stages and age win-
dows impact on neurodiagnostic performance is to investigate these variables along a single dis-
ease dimension, which is first spanned by ‘extreme’ or clearly distinct clinical phenotypes and then 
applied to the ‘intermediate’ or moderating conditions. This approach has been employed in the 
dementia field where morphometric patterns distinguishing patients with Alzheimer disease from 
healthy controls were used to quantify disease progression and severity in patients with Mild Cog-
nitive Impairment (Davatzikos et al., 2009). In the psychosis field, Y. Fan et al. (2008) employed 
this framework to trace the neuroanatomical schizophrenia (SZ) signature in unaffected first-
degree relatives of SZ patients, indicating that the latter display intermediate neuroanatomical phe-
notypes between patients and controls. Herein, we took a similar approach to explore the hypothe-
sis that the neuroanatomical signatures of major depression (MD), bipolar disorder (BIP), the at-
risk mental states for psychosis (ARMS) and SZ lie along a single direction spanned by MD and SZ 
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as the two end points of this continuum. Therefore, we first measured the single-subject separabil-
ity of stable SZ vs. MD in a representative database of 262 patients using MRI-based MVPA and 
then quantified differential diagnostic scores of independent persons with high-risk or first-episode 
states of psychosis (N=112) as well as patients with bipolar disorder (N=35). Second, we evaluated 
whether neurodiagnostic classification was moderated by important variables such as age of dis-
ease onset, disease stage and ‘accelerated aging’ effects (Koutsouleris et al., 2013) as well as 
cross-sectional psychopathological profiles overlapping between MD and SZ. We expected classi-
fication performance to be moderated by gradients of neuroanatomical SZ likeness increasing (1) 
from at-risk states to established schizophrenia, (2) from major depression, over bipolar disorder to 
schizophrenia, and (3) from later to earlier disease onsets across the life span. 
Materials & Methods 
Participants 
SZ and MD patients were examined at the Department of Psychiatry and Psychotherapy, Ludwig-
Maximilian-University Munich (LMU) using the Structured Clinical Interview for DSM-IV – Axis I & II 
Disorders (SCID-I/-II), the review of records and psychotropic medications and a semi-
standardized assessment of the psychiatric and somatic history. Patients’ symptoms were evaluat-
ed using standard psychometric scales (Table 1). Patients received a consensus diagnosis by two 
experienced psychiatrists at study inclusion and were excluded in case of an unstable SCID diag-
nosis over a four-year follow-up period. Further exclusion criteria were (1) a history of (a) schizoaf-
fective and/or bipolar disorder, (b) traumatic brain injury with loss of consciousness, mental retar-
dation, anorexia nervosa, delirium, dementia, amnestic disorders, personality disorders, substance 
dependence, as defined by DSM-IV, (c) previous electroconvulsive treatments, and (d) somatic 
conditions affecting the central nervous system, as well as (2) insufficient knowledge of German, 
IQ < 70, and age <18 or >65. Eleven MD patients fulfilled criteria for psychotic depression (DSM-
IV: 296.24/.34). Psychotic psychopathology in the MD group was further quantified by computing a 
composite Z score from the HAMD items ‘feelings of guilt’, ‘hypochondriasis’, ‘depersonalization 
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and derealisation’ and ‘paranoid symptoms’. This score was significantly elevated in patients with 
psychotic MD (MD-P: mean (SD): 1.2 (1.0); MD-NP: -0.2 (0.9); T=4.5, P<0.001). In the SZ group 
the severity of depressive symptoms was measured by summing the PANSS items ‘somatic con-
cern’, ‘anxiety’, ‘guilt feelings’ and ‘depression’ and Z transforming this PANSS-D score (El Yazaji 
et al., 2002; Kontaxakis et al., 2000). 
Patients with an illness duration of <1 year, no previous inpatient treatment and <12 months 
(life-time) psychopharmacological treatment (antipsychotics in SZ, antidepressants in MD) were 
assigned to first-episode (FE) subgroups, or to recurrently-ill (RE) samples, if they did not fulfil 
these criteria. These FE criteria were chosen to mitigate potential secondary disease effects (e.g. 
continuous medication and frequent hospitalization) on brain structure in the respective MD and SZ 
subgroups. Illness duration was the time between MRI scanning and disease onset defined retro-
spectively by the onset of symptoms paralleled by a general decline in social and role functioning 
(Lieberman et al., 2001). Following these definitions, the mean (SD) illness duration in the MD-FE / 
SZ-FE samples was 0.34 (0.24) / 0.37 (0.68) years, while the respective values for the MD-RE / 
SZ-RE were 9.19 (8.22) / 7.25 (7.14) years. Diagnosis had no significant main (F=1.53, P=.217) or 
interaction effects (F=1.63, P=.203) on illness duration in the FE and RE samples. 
The SZ vs. MD classifier was independently validated in 23 patients with first-episode psycho-
sis (Yung et al., 1998) recruited at the Department of Psychiatry, University of Basel and 89 ARMS 
individuals pooled across the LMU (N=52) and Basel (N=37) early recognition services, which were 
detailed in previous work (Koutsouleris et al., 2009) (Supplementary Methods & Table 1). ARMS 
individuals were stratified into an (1) early ARMS (ARMS-E, N=21) defined either by predictive 
basic symptoms OR a Global Functioning-Trait criterion, and (2) late ARMS (ARMS-L, N=68) de-
fined by attenuated or brief limited intermittent psychotic symptoms, which closely corresponded to 
internationally established high-risk criteria (Klosterkötter et al., 2001; Yung et al., 1998). Psychosis 
developed in 4.8% / 47.1% of ARMS-E / ARMS-L individuals over a follow-up period of 4.5 years 
(N=33, 87.9% diagnosed as SZ). At MRI, 61% / 95% of FEP / ARMS individuals were antipsychot-
ic-naïve (FEP: 6 with antipsychotic treatment for <1 month, and 3 for 1-3 months; ARMS: 4 treated 
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with low-dose atypical antipsychotics for <3 weeks). The diagnosis of FEP patients was evaluated 
5 years after baseline and all examined subjects met DSM-IV criteria for schizophrenic psychosis. 
Furthermore, classifier validation involved 35 LMU patients with an established SCID diagno-
sis of bipolar disorder (Table 1), who did not meet exclusion criteria 1(b)-(d) and 2. Thirty / Five of 
these patients fulfilled criteria for bipolar I / II disorder, with bipolar I patients showing depressive 
(N=11), manic (N=12), mixed episodes (N=3) and euthymic states (N=4). Psychotic episodes were 
present in 6 bipolar I patients (4 / 2 with manic / depressive states). 
Finally, 437 healthy volunteers (HC) previously described in Koutsouleris et al. (2013) and 
scanned at the same Munich scanner as the patient cohorts were used to correct the patients’ MRI 
data for age and sex effects as detailed below. The study was approved by each center’s local 
ethics committee. Written informed consent was obtained from each participant before inclusion. 
MRI data acquisition and preprocessing 
Study participants were scanned using two SIEMENS (Erlangen, Germany) MAGNETOM VISION 
1.5T scanners located at the University Hospital Basel and the Department of Radiology, Ludwig-
Maximilian-University. In Basel, a T1-weighted  three-dimensional volumetric spoiled gradient re-
called echo sequence generated 176 contiguous slices using the following protocol: time-to-echo 
(TE), 4 ms; time-to-repetition (TR), 9.7 ms; flip angle, 12; field of view (FOV), 25.6x25.6 cm, matrix, 
200x256; voxel dimensions, 1.28 x 1.0 x 1.0 mm. In Munich, a T1-weighted 3D-MPRAGE sequence 
was employed: TE, 4.9 ms; TR, 11.6 ms; FOV, 230 mm; matrix, 512 x 512; 126 contiguous axial 
slices; voxel dimensions, 0.45 x 0.45 x 1.5 mm. No calibration of MRI scanners was performed prior 
to or during the recruitment period.  
MRI preprocessing first involved the segmentation of T1-weighted images into gray (GM) and 
white matter (WM) as well as cerebro-spinal fluid using the VBM8 toolbox (see Koutsouleris et al. 
(2013) and Supplementary Methods) (Gaser, 2009). Then, the high-dimensional DRAMMS (Ou 
et al., 2011, 2014) algorithm registered each GM map to the single-subject MNI template. Result-
ing deformations and warped tissue maps were used to compute GM maps for a Regional Analysis 
of brain Volumes in Normalized Space (GM-RAVENS) (Davatzikos et al., 2001). 
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Correction for age and sex effects 
To remove age- and sex-related differences between patient groups while retaining disease-
associated neuroanatomical variation, the following strategy (Dukart et al., 2011) was employed: 
First, we calculated voxel-level β coefficients for age and sex in our HCs’ GM-RAVENS maps using 
partial correlation analysis. These coefficients described maps of (1) GM volume change from 18 
to 65 years-old HCs, and (2) GM volume differences between male and female HCs. Then we re-
sidualized the patient data using these coefficients to correct for age- and sex effects not attributa-
ble to disease-related factors. This strategy was validated in our Supplementary Methods. 
Differential diagnostic pattern classification 
We implemented a fully automated machine learning pipeline that extracted neuroanatomical fea-
tures from the GM-RAVENS maps and generated decision rules from these features to individually 
distinguish MD from SZ patients. To strictly separate the training process from the evaluation of the 
classifier’s generalizability, the pipeline was embedded into a repeated, double cross-validation 
framework (Filzmoser et al., 2009) (rdCV, Supplementary Methods), as detailed previously 
(Borgwardt et al., 2012; Koutsouleris et al., 2012). More specifically, the following analysis steps 
were wrapped into a 10x10-fold cross-validation cycle at the outer (CV2) and the inner (CV1) levels 
of rdCV: the training subjects’ GM-RAVENS maps were initially corrected for age and sex effects 
(see above) and then scaled voxel-wise to [0, 1]. To reduce the maps’ dimensionality and discard 
noisy information, Principal Component Analysis (PCA) (Hansen et al., 1999) projected correlated 
voxel sets to 170 uncorrelated eigenvariates, thus retaining 80% of the variance in each CV1 train-
ing partition. Correction, scaling, and PCA parameters were applied to the CV1 test data. Then, in 
each training partition, PCA features entered a recursive feature elimination algorithm (Guyon et 
al., 2002) that employed a linear SVM (R. Fan et al., 2008) to remove those eigenvariates that im-
paired separability on the respective CV1 test data (SVM penalty parameter: C=1).  
This process was repeated for all CV1 partitions, thus creating 100 diagnostic models for each 
CV2 partition. To obtain CV2 test predictions, the respective GM-RAVENS data were first pro-
cessed using the correction, scaling and PCA parameters of each CV1 training partition, and then 
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classified using the learned decision rules. Classification produced decision scores measuring the 
neuroanatomical SZ vs. MD likeness of a given subject. Finally, a CV2 test case’s group member-
ship was predicted by an ensemble classifier that averaged the decision scores of those 1000 CV1 
base learners in the rdCV, in which the subject had not been involved in the training process 
(Supplementary Methods). The BIP, FEP, ARMS-E and ARMS-L samples were processed iden-
tically to the CV2 test subjects. Finally, the classifier’s decision function was visualized in Figure 3 
and the underlying patterns of volumetric differences were quantified in Supplementary Figure 6. 
Testing differential diagnostic gradients in the ARMS and patient cohorts 
First, the decision scores generated by the differential diagnostic classifier entered ANOVAs that 
tested the hypotheses of neuroanatomical SZ likeness increasing (1) from the MD, through the 
BIP, to the SZ group, and (2) from the ARMS-E, through the ARMS-L to the FEP sample. In case 
of significant omnibus test statistics (P<0.05), post-hoc tests were carried out to evaluate pairwise 
differences at P<0.05, corrected for multiple comparisons using Tukey’s HSD test (Figure 1).  
Testing clinical and brain structural moderators of neurodiagnostic classification 
Second, potential moderating effects of disease stage on classification performance were evaluat-
ed at P<0.05 by stratifying MD and SZ patients into FE vs. RE subgroups and performing a χ2 test 
on the misclassification error in these samples. Then, the impact of age of onset and BrainAGE 
(Koutsouleris et al., 2013) on decision scores was investigated by median-splitting the SZ and MD 
groups according to the latter two variables. Main and interactions effects between decision scores 
and the factors ‘Diagnosis’, ‘Early vs. Late onset’, ‘Low vs. High BrainAGE’ were assessed at 
P<0.05 using the General Linear Model (Table 4, Figure 2, A). Further analyses evaluated if clas-
sification of early-onset/high-BrainAGE patients vs. late-onset/low-BrainAGE patients equaled di-
agnostic categorization (Figure 2, B1 & B2). Based on these analyses, we assessed the separa-
bility within and between onset-defined diagnostic subgroups by performing pairwise SVM anal-
yses as described above (Table 2).  
Third, we explored potential moderating effects of psychometric psychosis on neurodiagnostic 
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classification in MD by comparing the decision scores of patients with high (N=17) versus low 
(N=16) scores on the standardized composite scale of HAMD items 2, 15, 19 and 20. These MD 
subgroups were identified by thresholding the composite scale at Z > 1 and Z <-1. The same pro-
cedure was used to measure the effect of psychometric depression on neurodiagnostic classifica-
tion in SZ: Identical Z thresholds were applied to the standardized PANSS-D subscale and neuro-
anatomical decision scores were compared between the resulting SZ subgroups with high (N=30) 
and low (N=20) depression scores. Finally, correlations between the decision scores and additional 
clinical variables of the MD and SZ samples were analyzed in the Supplementary Table 1. 
Results  
Sociodemographic and clinical variables: SZ and MD patients groups did not differ regarding 
handedness, BMI, schooling years, nicotine or alcohol consumption (Table 1). Patient groups dif-
fered in the prescribed antipsychotic, antidepressant and mood-stabilizing medications. However, 
all these variables had no effect on neurodiagnostic decision scores (Supplementary Table 1). 
Group-level differences were observed for age at scan, sex and age of disease onset, but not ill-
ness duration. Finally, SZ patients had a higher mean (SD) BrainAGE score of +5.99 (6.00) com-
pared to MD (+4.04 (6.19)).  
Neuroanatomical classification and influence of moderating variables: The MRI classifier 
diagnosed unseen MD and SZ patients with a balanced accuracy (BAC) of 76% (sensitivity / speci-
ficity = 79.8% / 72.2%, diagnostic odds ratio = 10.2; Table 2). Recurrently-ill patients were more 
likely misclassified compared to first-episode patients (Error rates MDFE / SZFE: 15.0% / 11.5%; 
MDRE / SZRE: 23.4% / 28.8%; χ2=6.6; P=.010). The neuroanatomical decision function (Figure 3) 
involved GM reductions in SZ vs. MD covering the perisylvian structures (inferior frontal, insular, 
supramarginal, angular, superior temporal and temporopolar cortices) with extensions to the or-
bitofrontal, inferior temporal and medial temporal cortices. Further reductions covered the ventro-
medial prefrontal, anterior cingulate, medial parietal, occipital and dorsolateral prefrontal cortices. 
GM reductions in MD vs. SZ were localized in a spatially distinct pattern including the brainstem 
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regions, cerebellum, periventricular areas and the somatosensory cortices, extending to the pre-
motor, parietal and supplementary motor areas. 
The medians of age of onset / BrainAGE used to stratify patients were 36.3 / +3.57 in the MD 
and 23.8 / +5.62 in the SZ sample. The GLM evaluating effects of diagnosis, age of onset and 
BrainAGE factors on diagnostic scores detected significant main effects as well as a significant 
interaction between the ‘diagnosis’ and ‘early vs. late’ factors (Table 3). Box plot analyses showed 
that early disease onset and high BrainAGE increased SZ likeness in both disease groups, with 
this effect being more pronounced in the MD compared to the SZ (Figure 2, A). Using the diagnos-
tic decision scores, late-onset, low-BrainAGE patients were separable from early-onset, high-
BrainAGE patients to a similar degree (AUC=.77) as MD from SZ patients (AUC=0.80, Figure 2, 
B1 & B2). Finally, the onset-stratified subgroup classification showed (1) a better separability of 
early vs. late-onset MD patients (BAC=83.7%) than early vs. late-onset SZ patients (62.3%, Table 
2), and (2) a particularly low separability of early-onset MD vs. late-onset SZ patients (57.4%). 
When diagnostic subgroup probabilities were collapsed into MD vs. SZ diagnoses, the BAC was 
lower (72.2%) than in the original whole-group analysis. 
The comparison of the neurodiagnostic scores in SZ patients with high vs. low psychometric 
depression scores (mean (SD): -0.59 (1.30) vs. -0.57 (0.98)) did not yield significant differences 
(T=-0.04; P=0.966). Similarly, MD patients with high psychometric psychosis scores did not signifi-
cantly differ from patients with low scores (mean (SD): 1.64 (1.41) vs. 0.77 (1.17); T=1.88; 
P=0.071). Additionally, MD patients with vs. without a DSM-IV diagnosis of psychotic depression 
did not differ in their neurodiagnostic scores (1.25 (1.63) vs. 0.84 (1.24); T=0.98; P=0.331) nor in 
their misclassification rates (20.0% vs. 20.2%; χ2=0.00; P=1.000). 
Presence of a SZ-like neuroanatomical signature in ARMS, FEP and BIP subjects: Decision 
scores obtained from the independent validation data showed that SZ likeness was most pro-
nounced in the Basel FEP patients (86.9% labeled as SZ, Figure 1) followed by the cross-center 
ARMS-L group (77.9%) and the Munich ARMS-E sample (61.0%). SZ likeness was lower in the 
Munich BIP group (25.7%) resulting in 74% of these patients being classified as MD. Significant 
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group differences were detected in all pairwise post-hoc contrasts of the MD vs. BIP vs. SZ com-
parison (Figure 1). In the ARMS-E vs. ARMS-L vs. FEP analysis, we observed a significant in-
crease of SZ likeness in the ARMS-L compared to the ARMS-E group (P=0.042) with the former 
being on par with the FEP sample (P=1.000). 
Discussion 
This is to our knowledge the first structural MRI study to report a cross-validated, single-subject 
separability of 76% in a representative cohort of patients with a stable diagnosis of either schizo-
phrenia or major depression. This finding is in keeping with the balanced accuracy of 78% reported 
by Ota et al. (2013) who examined 25 age-matched female patients with SZ or MD using fractional 
anisotropy and GM volumes in predefined regions-of-interest. We observed that neuroanatomical 
markers successfully generalized to patients with first-episode psychosis who were examined at an 
independent center using a different MRI protocol and were prospectively diagnosed with schizo-
phrenia. Validation also showed that diagnostic sensitivity extended to the ARMS and grew with 
symptomatic proximity to overt psychosis. Strikingly, the neurodiagnostic classifier assigned 74% 
of patients with bipolar disorder to the MD group, suggesting that schizophrenia may be differenti-
ated from mood disorders at the single-subject level. In addition, we did not find evidence that neu-
rodiagnostic classification was significantly influenced by the presence of psychotic symptoms in 
MD or depressive symptoms in SZ patients, nor by life-style factors or different medications at the 
time of MRI scanning (Supplementary Table 1). However, we identified a neuroanatomical signa-
ture shared by SZ and MD patients with an average disease onset at 26.5 years (Supplementary 
Table 2) and accelerated brain aging effects (Koutsouleris et al., 2013), which led to a non-
separability of these subgroups.  
Our findings partly agree with recent studies that used structural imaging data (Ota et al., 
2013) or Near Infrared Spectroscopy (Takizawa et al., 2014) to differentiate between functional 
psychoses at the single-subject level. However, comparability to these studies is limited because 
we did not mitigate naturally occurring demographic differences between SZ and MD by studying 
matched patient samples. Instead, we adjusted our data using a representative database of 
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healthy controls that fully covered the age range of our patient population (Dukart et al., 2011). 
Therefore, potential confounds like divergent illness durations and equalized sex distributions were 
avoided a priori. This approach facilitated the evaluation of the neurodiagnostic pattern, its pres-
ence in partly overlapping clinical phenotypes and its clinical moderators across the adult life span: 
First, we identified a pattern of perisylvian, prefrontal and temporo-limbic GM volume reductions 
used by the classifier to separate SZ from MD at the single-subject level. Similar patterns were 
repeatedly described to distinguish patients with schizophrenia from healthy controls (Bora et al., 
2011; Honea et al., 2005) and were interpreted in line with a disconnection syndrome (Friston, 
1999) underlying the cognitive, perceptual and thought disturbances of psychosis (Modinos et al., 
2012; Sans-Sansa et al., 2013). Our finding of a GM volume reduction signature (Supplementary 
Figure 6) in SZ compared to MD patients, who were on average 11.5 years older, adds to the con-
cept of schizophrenia being a neurodevelopmentally mediated, cognitive illness (Kahn and Keefe, 
2013) marked by more unfavorable disease outcomes compared to unipolar depression (Harrow et 
al., 2000). In contrast, somatosensory, periventricular and subcortical abnormalities distinguished 
MD from SZ in line with previously reported structural abnormalities in major white matter tracts of 
depressed patients (Disabato et al., 2014; Guo et al., 2014). Alterations of these regions may sub-
serve core features of depression, such as psychomotor and mood disturbances (Serafini et al., 
2010). 
Second, the high rate of MD classifications in our BIP sample suggests that bipolar disorder 
and unipolar depression share a common structural denominator different from schizophrenia in 
line with Kraepelin’s original dichotomic concept of functional psychoses (Kraepelin, 1899). This 
finding agrees with initial reports of a good single-subject separability of SZ and BIP based on 
structural (Schnack et al., 2014) or functional MRI (Costafreda et al., 2011). It may also point to an 
increased sensitivity of MVPA techniques in detecting points of rarity in high-dimensional neuroim-
aging data compared to univariate methods, which frequently reported considerable overlaps be-
tween bipolar disorder and schizophrenia (Arnone et al., 2009). On the other hand, we found a 
significant difference in the neurodiagnostic scores of the MD and BIP groups (Figure 1), which 
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adds to the growing evidence for a neurobiological signature separating these two largely overlap-
ping conditions (Redlich et al., 2014). Hence, future studies with access to larger sample sizes in 
the bipolar and schizoaffective categories are needed to directly quantify the neurodiagnostic sepa-
rability of these ‘intermediate’ phenotypes (Mathew et al., 2014), thus providing a comprehensive 
picture of continuities and discontinuities in the functional psychoses spectrum (Laursen et al., 
2009).  
Third, we found that an earlier disease occurrence correlated with lower differential diagnostic 
accuracy, rendering MD patients with earlier disease onsets inseparable from SZ patients – de-
spite distinct cross-sectional phenotypes. This observation was corroborated by the high separabil-
ity of age of onset-defined MD samples (83.7%, Table 2) compared to the respective SZ sub-
groups (62.3%), which suggests that neuroanatomical surrogates of depressive syndromes strong-
ly covary with the disease onset axis. This hypothesis has recently received support from studies 
showing a pronounced thinning in prefrontal, cingulate, precuneal and inferior temporal cortices of 
early vs. late-onset MD patients and healthy controls (Truong et al., 2013) (see Supplementary 
Figure 5). Hence, our results may point to more disrupted neurodevelopmental processes in early 
depression, potentially manifesting as an accelerated brain aging effect (Koutsouleris et al., 2013). 
These processes may also be linked to a more severe clinical phenotype of depression, entailing 
greater illness severity, higher relapse rates, more cognitive disturbances, as well as overall poorer 
disease outcomes and higher familial co-aggregation with schizophrenia (Dekker et al., 2007; 
Korten et al., 2012; Maier et al., 1993; Zisook et al., 2004). Hence, the overlaps between schizo-
phrenia and early-onset depression may lead to a diagnostic dilemma, particularly in the early 
phases of these illnesses when overt psychotic symptoms have not yet evolved or patients are not 
explored during psychotic phases. Our results indicate that this challenge cannot be resolved by 
our neuroanatomical classifier, which would frequently diagnose these early-onset depressed pa-
tients with schizophrenia. Thus, it remains to be elucidated whether different imaging modalities 
and combinations thereof may help increasing the diagnostic specificity in the neurobiological clas-
sification of early-onset depression. 
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Fourth, we observed an increasing SZ likeness from ARMS-E to FEP, suggesting that the neu-
rodiagnostic fingerprint of schizophrenia is already detectable in persons with basic symptoms, and 
further intensifies as attenuated, brief limited intermittent and frank psychotic symptoms emerge. 
This finding agrees with previous studies reporting longitudinal GM volume changes in the ARMS, 
indicating a progressive course of neuroanatomical alterations as the at-risk state evolves into 
overt psychosis (Cannon et al., 2014; Koutsouleris et al., 2010). However, due to the cross-
sectional design of our study, it remains unclear (1) whether the increase of SZ-likeness along 
these early states of psychosis also occurs at the level of neuroanatomical disease trajectories, 
and (2) which protective factors contribute to a non-conversion to psychosis despite the presence 
of the SZ-specific pattern in a given patient.   
Finally, one caveat has to be considered when interpreting our findings: different medication 
and treatment histories in our SZ vs. MD groups may have influenced the separability of our pa-
tients as long-standing antipsychotic treatment has been previously shown to interact with disease-
related brain changes (Ho et al., 2011). Although life-time medication data was not available for the 
current dataset, the high diagnostic sensitivity in our minimally treated ARMS and FEP groups ar-
gues against major treatment effects on our results. Furthermore, our finding of a significantly 
higher classification performance in first-episode compared to recurrently-ill patients is at odds with 
the expectation that relapsing illness stages and - in consequence – accumulating disease-specific 
treatment effects would increase the neuroanatomical gaps between schizophrenia and unipolar 
depression. The higher diagnostic error in the recurrently-ill patient sample could be interpreted as 
a dilution effect, which may arise from increasing neuroanatomical heterogeneity as patients 
evolve along divergent disease trajectories. Hence, this heterogeneity may result from (1) structur-
al brain variation linked to differential disease courses (Mourao-Miranda et al., 2012) and treatment 
outcomes (Palaniyappan et al., 2013), (2) distinct neuroanatomical correlates of positive, negative, 
disorganized and depressive subsyndromes of schizophrenia, as revealed by factor analytic stud-
ies (Koutsouleris et al., 2008; Nenadic et al., 2010, 2012; Zhang et al., 2014), and (3) temporal 
shifts of these profiles over time, with negative and depressive symptoms becoming increasingly 
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prominent in the course of the disease (Salvatore et al., 2013). Nevertheless, our results did not 
support a moderating or ‘diluting’ effect of depressive / psychotic syndromes in SZ / MD on neuro-
diagnostic classification performance. Thus, the strong impact of longitudinal disease variables 
such age of disease onset and disease stage may suggest that the identified neuroanatomical bi-
omarker is linked to the temporal and neurodevelopmental characteristics of these clinical pheno-
types rather than to their cross-sectional psychopathological features (Gogtay et al., 2011). 
In summary, our findings partly confirm and partly question the Kraepelinian dichotomy of 
functional psychoses into schizophrenia and affective disorders. This is not surprising if one con-
siders the plethora of studies in support of either a phenomenological and neurobiological continu-
um or a division between these two nosological groups (Kotov et al., 2013). Our results suggest 
that the diagnostic boundaries drawn by a neuroanatomical disease signature become increasingly 
porous as patients develop depressive disorders at younger ages, potentially mediated by a cross-
nosological disruption of neurodevelopmental processes. This gradient of diagnostic uncertainty 
does not only challenge clinical and biomarker-based diagnosis, it highlights also the utility of pat-
tern recognition methods to probe the neurological basis of psychiatric illnesses and potentially 
refine nosological disease constructs. 
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Figures Legends 
 
Figure 1: Box plot comparison and ANOVAs of SVM decision values including the MD & SZ 
training database (light grey) and independent validation data consisting of BIP, ARMS and FEP 
samples (dark grey). Box plots describe decision value distributions in terms of 5%, 25%, 50%, 
75% and 95%-CIs. Frequency of SZ-positive diagnosis is measured as percentage of subjects per 
group labeled as SZ by the classifier (top of the box plot chart). P values of post-hoc comparisons 
in both ANOVAs are provided below and were corrected for multiple comparisons using Tukey’s 
HSD method (SPSS version 20, IBM Inc.). 
Figure 2: Box plot and ROC analyses comparing the separability of diagnosis-based vs. age 
of onset & BrainAGE-based patient groups. A1: Effects of age of onset (left) and BrainAGE 
(right) on diagnostic separability in MD vs SZ patients. B1: Diagnostic separability of diagnostic 
groups (MD vs SZ, left) vs. separability in cross-nosological patient groups (right) defined by early 
vs. late disease onset (EO vs LO) and high vs low BrainAGE (Br+ vs. Br-). B2: ROC analyses of 
MRI-based decision scores in the classification of diagnosis (left) and EO/Br+ vs. LO/Br- groups. 
Figure 3: Voxel probability map (VPM) of reliable contributions to the MD vs. SZ decision 
boundary. Voxels with a probability of >50% were overlaid on the single subject MNI template 
using the MRIcron software package (http://www.mccauslandcenter.sc.edu/mricro/mricron/). Meth-
odological descriptions on how the VPMs were computed can be found in the Supplementary 
Methods section. 
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Table 1: Sociodemographic and clinical characteristics of study groups. Descriptive analyses between MD and SZ patient groups 
were performed by means of chi2-tests for categorical data (†) and t tests for continuous data (‡) t tests. Abbreviations: BMI Body-
Mass-Index, BPRS Brief Psychiatric Rating Scale, BrainAGE Brain Age Gap Estimation score, cig. cigarettes, HDRS Hamilton Depres-
sion Rating Scale, P significance, PANSS Positive and Negative Symptom Scale, yrs. years, SD standard deviation, YMRS Young 
Mania Rating Scale.  
         
 Training and cross-validation database Independent validation database 
Sociodemographic &  
Clinical Variables MD SZ T P BIP FEP ARMS-E ARMS-L 
N 104 158   35 23 21 68 
N Basel [%] / Munich [%] 0 / 100 0 / 100   0 / 100 100 / 0 0 / 100 54 / 46  
Mean age at baseline [yrs.] 
(SD) 42.3 (12.0) 30.8 (10.0) 8.1‡ <.001 39 (9.6) 26.8 (6.5) 25.6 (5.6) 24.6 (5.9) 
Sex (male) [%] 50 74 15.8† <.001 51 74 48 68 
Handedness (right) [%] 95 91 1.5† ns 85 78 81 90 
BMI [kg/m2] (SD) 24.7 (4.6) 24.3 (4.4) 0.7‡ ns 25.6 (3.6) -- 21.1 (2.4) 23.0 (3.3)m 
Schooling [yrs.] (SD) 10.6 (2.0) 10.6 (2.1) 0.2‡ ns 11.6 (1.6) 10.0 (1.6) 11.5 (2.9) 11.1 (1.5) 
Nicotine [cig./day] 9.7 (13.4) 13.2 (13.7) -1.96‡ ns 11.4 (13.1) -- 7.0 (9.9) 7.0 (9.8)m 
Alcohol [g/day] 11.2 (21.1) 11.2 (25.5) -0.01‡ ns 5.6 (20.6) -- 2.9 (5.6) 7.7 (15.3)m 
Mean age of disease onset 
[yrs.] (SD; Median) 36.5 (12.0) 25.5 (8.0) 8.1‡ <.001 26.1 (9.1) -- -- -- 
Mean illness duration [yrs.] (SD) 6.0 (7.8) 4.5 (7.0) 1.4‡ ns 13.9 (9.2) -- -- -- 
Current treatment with typical 
antipsychotics [%] 10.0 30.7 17.7† <.001 0.0 0.0 -- -- 
Current treatment with atypical 
antipsychotics [%] 9.0 67.3 86.7† <.001 40.0 39.1 -- -- 
Current chlorpromazine equiva-
lents [mg/d] 43.1 (162.0) 346.3 (373.4) -8.6‡ <.001 189.2 (322.9) 244.0 (163)     -- -- 
Current treatment with antide-
pressants [%] 73.1 7.9 156.7† <.001 16.7 21.7 23.8 12.9 
Current treatment with mood 
stabilizers [%] 13.0 3.3 8.1† <.01 66.7 0.0 0.0 0.0 
Current treatment with lithium 
[%] 7.0 0.0 10.† <.01 16.7 0.0 0.0 0.0 
Mean BPRS (SD)     -- 52.7 (13.6) -- 41.9 (10.6)b 
Mean PANSS total (SD) -- 52.6 (29.2) -- -- -- -- 56.8 (14.0) 62.0 (22.2) 
Mean PANSS positive (SD) -- 11.9 (8.0) -- -- -- -- 9.86 (2.6) 13.7 (4.5) 
Mean PANSS negative (SD) -- 15.2 (9.7) -- -- -- -- 14.9 (6.7) 15.7 (8.5) 
Mean PANSS general psycho-
pathology (SD) -- 25.6 (16.1) -- -- -- -- 32.0 (7.9) 32.6 (11.1) 
Mean SANS (SD) -- 45.0 (26.8) -- -- -- 10.0 (5.3) -- 9.5 (5.4)b 
Mean HDRS (SD) 21.3 (9.5) -- -- -- 9.7 (9.8) -- -- -- 
Mean YMRS (SD)     11.0 (12.0) -- -- -- 
BrainAGE [yrs.] (SD) 4.0 (6.2) 6.0 (6.0) -2.55‡ <.05 3.8 (6.5) 5.1 (8.5) -1.5 (7.7) 2.7 (6.8) 
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Table 2: Diagnostic performance: The performance of the MRI diagnostic system was evaluated by means of 
sensitivity (Sens), specificity (Spec), balanced accuracy (BAC), false positive rate (FPR), positive / negative predic-
tive value (PPV / NPV) and Diagnostic Odds Ratio (DOR). These measures were calculated from the confusion ma-
trix containing the number of true positives (TP), false negatives (FN), true negatives (TN) and false positives (FP). 
Abbreviations: MD-E early-onset MD, MD-L late-onset MD, SZ-E early-onset SZ, SZ-L late-onset SZ 
 
Dataset TP TN FP FN Sens 
[%] 
Spec 
[%] 
BAC 
[%] 
FPR 
[%] 
PPV 
[%] 
NPV 
[%] 
DOR 
Cross-validation 83 114 44 21 79.8 72.2 76.0 27.8 65.4 84.4 10.2 
MD [+1] vs. SZ [-1] (Munich)            
Age-of-onset stratified multi-
group classifier            
MD-E vs. SZ-E 38 51 24 14 73.1 68.0 70.5 30.2 61.3 78.5 5.8 
MD-E vs. MD-L 42 45 7 10 80.8 86.5 83.7 13.5 85.7 81.8 27.0 
MD-E vs. SZ-L 31 42 34 21 59.6 55.3 57.4 44.7 47.7 66.7 1.82 
SZ-E vs. MD-L 67 52 0 8 89.3 100.0 94.7 0.0 100.0 86.7 -- 
SZ-E vs. SZ-L 47 47 29 28 62.7 61.8 62.3 38.2 61.8 62.7 2.72 
MD-L vs. SZ-L 46 64 12 6 88.5 84.2 86.3 15.8 79.3 91.4 40.9 
MD vs. SZ (collapsed) 79 104 47 25 76.0 68.9 72.4 31.1 62.7 80.6 6.99 
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Table 3: Moderators of MRI-based differential diagnosis. Main and two-way interaction effects of 
diagnosis, early vs. late disease onset and low vs. high BrainAGE on diagnostic scores were ana-
lyzed using univariate linear modelling in SPSS (version 20, IBM Inc.). Abbreviations: E estimate 
(mean difference or marginal mean), SE standard error, 95%-CI Low / Up 95%-confidence interval 
with lower and upper bounds, F F-statistic. 
 
Dataset E SE 95%-CI 
Low / Up 
F P 
Main effects      
MD vs. SZ [mean difference] 1.49 0.13 1.24 / 1.75 134.0 <.001 
MD [marginal mean] 0.89 0.10 0.70 / 1.09   
SZ [marginal mean] -0.60 0.08 -0.76 / -0.44   
Early vs. Late-Onset -1.03 0.13 -1.29 / -0.78 62.6 <.001 
Early-Onset -0.37 0.09 -0.55 / -0.19   
Late-Onset 0.66 0.09 0.48 / 0.85    
Low vs. High BrainAGE 0.41 0.13 0.15 / 0.67 9.8 .002 
Low BrainAGE 0.35 0.09 0.17 / 0.53   
High BrainAGE -0.06 0.09 -0.24 / 0.13   
Two-way interaction effects      
MD vs. SZ  ͯEarly vs. Late-Onset    8.3 0.004 
MD ͯ Early-Onset 0.19 0.14 -0.09 / 0.47   
MD ͯ Late-Onset 1.59 0.14 1.32 / 1.88   
SZ  ͯEarly-Onset -0.93 0.12 -1.16 / -0.70   
SZ  ͯLate-Onset -0.27 0.12 -0.50 / -0.04   
MD vs. SZ ͯ Low vs. High BrainAGE    3.7 0.056 
MD ͯ Low BrainAGE  1.22 0.14 0.95 / 1.50   
MD ͯ High BrainAGE  0.56 0.12 0.29 / 0.84   
SZ  ͯLow BrainAGE  -0.52 0.12 -0.74 / -0.29   
SZ  ͯHigh BrainAGE -0.68 0.12 -0.91 / -0.44   
 
 
